DBV Technologies Screens First Subject in Phase 2 Study of Peanut Allergy Patch Trial
MT Newswires Live
Jun 03
DBV Technologies (DBVT) has screened the first participant in a phase 2 study evaluating the Viaskin Peanut patch in infants with peanut allergy aged 6 to 12 months, the company said Tuesday.
Participants will receive daily treatment with the peanut patch for 36 months, while maintaining a peanut-free diet, DBV technologies said.
After 36 months, participants will undergo a peanut food challenge to determine their treatment regimen for the next 12 months. Depending on the results, some participants will discontinue the patch during the peanut consumption period, while others will continue treatment, the company said.
Shares of the company were down over 3% in Wednesday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.